Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Cash Flows
Net loss	$ (13,193,000)	$ (30,621,000)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation - services	787,000	563,000
Stock based compensation - prepaid	0	0
Stock issued from equity incentive plan	(50,000)	22,000
Gain from settlement of accounts payable	0	(62,000)
Gain from extinguishment of debt	(741,000)	0
Change in fair value of contingent share consideration	(1,775,000)	5,779,000
Change in fair value of convertible promissory notes	393,000	9,380,000
Reserve on investment	350,000	0
Depreciation and amortization	3,607,000	918,000
Amortization of loan discounts	0	1,500,000
Bad debt expenses	41,000	46,000
Recovery of bad debt expense	(221,000)	0
Loss on disposal of property, plant and equipment	41,000	0
Inventory reserve for obsolescence	(176,000)	292,000
Change of fair value in derivative liabilities	0	(91,000)
Fair value of vested stock options and restricted stock	3,143,000	2,839,000
Warrant granted for broker fee expense	0	119,000
Change in operating assets and liabilities:
Accounts receivable	(174,000)	(59,000)
Inventory	(239,000)	(147,000)
Prepaid expenses and other assets	929,000	300,000
Other assets	(25,000)	(2,000)
Accounts payable	744,000	493,000
Accrued expenses	2,822,000	455,000
Finance lease payable	(12,000)	(11,000)
Contract liabilities	(486,000)	(1,425,000)
License fees	(80,000)	(10,000)
Cash used in operating activities	(4,315,000)	(9,722,000)
Cash flows from investing activities
Investment in company	(57,000)	(250,000)
Purchase of intangible assets	83,000	15,000
Net cash acquired from acquisition of Sera Labs, Inc.	0	1,357,000
Acquisition of property and equipment, net	(35,000)	(673,000)
Purchase of note receivable	(200,000)	(1,550,000)
Collection of note receivable	200,000	1,000,000
Cash used in investing activities	(175,000)	(131,000)
Cash flows from financing activities
Proceeds from convertible notes payable	0	5,000,000
Proceeds from loans payable	279,000	204,000
Proceeds from exercise of warrants	0	1,418,000
Proceeds from related party payable	796,000	150,000
Proceeds from notes payable	2,015,000	1,850,000
Proceeds from paryoll protection program loan	0	399,000
Repayment of notes payable	0	(1,100,000)
Repayment of related party payable	0	(250,000)
Repayment of loans payable	(309,000)	(189,000)
Cash provided by financing activities	2,781,000	7,482,000
Net decrease in cash and cash equivalents	(1,709,000)	(2,371,000)
Cash and cash equivalents, beginning of year	1,725,000	4,096,000
Cash and cash equivalents, end of year	16,000	1,725,000
Supplemental cash flow information
Interest	226,000	3,000
Income Tax	0	0
Non-cash investing and financing activities:
Common stock issued for conversion of promissory notes and accrued interest	4,146,000	2,196,000
Common stock issued for settlement of earnout liabilities from the acquisiton of Chemistry Holdings, Inc	0	21,701,000
Assets received from acquisition of The Sera Labs, Inc.	0	1,830,000
Goodwill received from acquisition of The Sera Labs, Inc.	0	4,687,000
Customer relationship, non-compete, and trademark resulting from acquisition of The Sera Labs, Inc.	0	10,182,000
Liabilities assumed from acquisition of The Sera Labs, Inc.	0	4,091
Contingent shares consideration for acquisition of The Sera Labs, Inc.	0	3,083,000
Related party note payable resulting from acquisition of The Sera Labs, Inc.	0	1,141
PPP loan assumed from acquisition of The Sera Labs, Inc.	$ 0	$ 206,000